Research programme: erythropoietin dimer - Beth Israel Deaconess Medical Center/DNAPrint Genomics

Drug Profile

Research programme: erythropoietin dimer - Beth Israel Deaconess Medical Center/DNAPrint Genomics

Alternative Names: PT-401; Super EPO dimer

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Beth Israel Deaconess Medical Center
  • Class Erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Anaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anaemia in USA
  • 09 Apr 2008 Pharmacodynamics data from a preclinical study presented at the 109th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2008)
  • 05 Apr 2005 Preclinical trials in Anaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top